The way I see it is as follows in terms of the MPS programs:
- MPS VI We are at Phase 2/3 for Europe and US....The IND will most likely be Q1 2021, this trial should go for a year and then we have the read out
- MPS I has also been badged as orphan status. I think this is more of an exploratory trial in Adelaide. Based on the strength of the MPS VI (P2/P3 combined - Europe and US) and on success of MPS I Phase 2 (Adelaide), this may be enough to qualify us to be licensed to use iPPS to tackle both strains of MPS (I and VI) and garner revenue in this area.
I might have this wrong, but I think thats the gist.
So yes Mixed Bag, you are right, 10 patients for the Adelaide P2 Trial wouldn't be enough on its own in my view. But combining this with the main MPS (VI) trial that will start next year is the main pathway.
- Forums
- ASX - By Stock
- PAR
- Chart
Chart, page-1415
-
- There are more pages in this discussion • 2,880 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAR (ASX) to my watchlist
|
|||||
Last
24.5¢ |
Change
-0.010(3.92%) |
Mkt cap ! $85.70M |
Open | High | Low | Value | Volume |
24.5¢ | 25.0¢ | 24.0¢ | $59.66K | 241.2K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 78837 | 24.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
25.0¢ | 36290 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 78837 | 0.245 |
3 | 44840 | 0.240 |
5 | 111000 | 0.235 |
5 | 125200 | 0.230 |
6 | 135884 | 0.225 |
Price($) | Vol. | No. |
---|---|---|
0.255 | 46689 | 5 |
0.260 | 106349 | 3 |
0.265 | 30000 | 1 |
0.270 | 20000 | 2 |
0.275 | 13636 | 2 |
Last trade - 16.10pm 30/08/2024 (20 minute delay) ? |
Featured News
PAR (ASX) Chart |
The Watchlist
1CG
ONE CLICK GROUP LIMITED
Mark Waller, MD
Mark Waller
MD
Previous Video
Next Video
SPONSORED BY The Market Online